New drug may stop aggressive lymphoma relapse after transplant or CAR-T
NCT ID NCT05256641
First seen Nov 11, 2025 · Last updated Jun 10, 2026 · Updated 29 times
Summary
This study tests whether a daily pill called acalabrutinib can help prevent relapse in people with very high-risk large B-cell lymphoma after they have received a stem cell transplant or CAR-T cell therapy. The drug works by blocking a protein that helps cancer cells grow. The trial will enroll 24 adults aged 18-70 and will check how well the drug is tolerated and whether it improves the chance of staying cancer-free for at least one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Oklahoma
NOT_YET_RECRUITINGOklahoma City, Oklahoma, 73190, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.